报价延迟最少15分钟:2025/07/20 13:13 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.14 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.85/-2.14
|
|
企业价值
14.23M
|
| 资产负债 |
|
每股账面净值
2.79
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
43.95M
|
|
每股收益
1.30
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:13 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program,HB-500, are being developed in partnership with Gilead. |
